AKT cancer cell pathway demonstrates unexpected function
22nd Nov 2005, 17:31 GMT
In investigating the molecular mechanisms of cancer cell motility - the unique property that enables cancer to spread from its primary origin to other parts of the body - researchers have uncovered a surprising role for the AKT/PKB (protein kinase B) enzyme, providing important new insights into cancer metastasis and suggesting that current efforts to develop cancer therapies by inhibiting AKT may be inadvertently promoting the spread of the disease.
AKT cancer cell pathway demonstrates unexpected function related news:
- AKT cancer cell pathway demonstrates unexpected function — RedOrbit News - Health
- Plant Compound May Block Tobacco-Induced Lung Cancer — Medical News Today RSS/XML Feed
- The variable cell — Nature Signaling Update
- On the verge of collapse — Nature Signaling Update
- [Pharmacology] Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress — Proceedings of the National Academy of Sciences recent issues
- Stem cell researchers choose Singapore over Stanford — SacBee -- AP State Wire News
- Einstein scientists discover how protein crucial for motion is synthesised at the right place in the cell — EurekAlert! - Cancer
- Killing regulatory T cells boosts effectiveness of cancer vaccine — EurekAlert! - Medicine and Health
- Compound from Salinispora (marine bacteria) kills blood cancer cells — News-Medical News Feed
- Letzter Akt: Schröder legt Bundestagsmandat nieder — tagesschau.de - Die Nachrichten der ARD
Latest news from EurekAlert! - Cancer:
- Targeted cancer drugs may work by disrupting balance of cellular signals
- Studies examine colorectal cancer screening rates
- Higher red meat intake may increase risk for certain breast cancers
- U-M researchers use nanoparticles to target brain cancer
- 'Trojan Horse' agent halts bone metastasis in mice
- Increased patient demand for prostate test has serious implications for cancer services
- Novel regulatory mechanism identified for key tumor suppressor p53